Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1996-04-10
1998-03-17
Ivy, C Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
560158, A61K 3127, C07C27110
Patent
active
057287287
ABSTRACT:
Novel methods are disclosed for treating acute and chronic neurological disease and attenuating further neuronal cell death in neurological diseases, employing a glycine site antagonist at the NMDA (N-methyl-D-aspartate) complex, e.g., 2-phenyl-1,3-propanediol dicarbamate (felbamate).
REFERENCES:
patent: 4978680 (1990-12-01), Sofia
patent: 5292772 (1994-03-01), Sofia
patent: 5492930 (1996-02-01), Coffin
Amaee, F. R. et al., NG-methyl-L-arginine protects the guinea pig Cochlea from the Cytotoxic effects of Pneumolyfin, Acta OTO-Laryngolo-Gica, vol. 115 (3), pp. 386-391, 1995.
Hayes, M.P. et al, Brain (1993), 116, 1425-1450, "A mechanism of quinolinic acid formation by brain in inflammatory neurological disease". "d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study".
Serra, M. et al, European Journal of Pharmacology 265 (1994) 185-188, "Felbamate antagonizes isoniazid- anti FG 7142-induced reduction of GABA.sub.A receptor function in mouse brain".
Fletcher, E.J. et al, European Journal of Pharmacoloqy, 235 (1993) 291-295, "Haloperidol interacts with the strychnine-insenitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones".
White, H.S. et al, Epilepsy Research 20 (1995) 41-48, "Felbamate modulates the strychnine-insensitive glycine receptor".
Melis, M.R. et al, Neuroscience Letters 179 (1994) 9-12, "Nitric oxide synthase inhibitors prevent N-methyl-D-aspartic acid-induced penile erection and yawning in male rats".
Hayashi, T., Department of Physiology, School of Medicine, Keio University, (Received for publication Jul. 10, 1952), "A Physiological Study of Epileptic Seizures Following Cortical Stimulation in Animals and Its Application To Human Clinics".
Baxter, M.G. et al, Neurobiology of Aging, vol. 15, No. 2, pp. 207-213, 1994, "D-Cycloserine, a Novel Cognitive Enhancer, Improves Spatial Memory in Aged Rats".
Carlson, M.D. et al, Neurobiology of Aging, vol. 14, pp. 343-352, 1993, "NMDA, AMPA and Benzodiazepine Binding Site Changes in Alzheimer's Disease Visual Cortex".
Carter, A.J., Drugs of the Future, 1992, 17(7): 595-613, "Glycine antagonists: Regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site".
Cheshire, W.P., The Clinical Journal of Pain, vol. 11, No. 2, 139-142 (1995) "Felbamate Relieved Trigeminal Neuralgia".
Chronopoulos, A. et al, Epilepsia, 34(2):359-366, 1993, "Neuroprotective Effect of Felbamate After Kainic Acid-Induced Status Epilepticus".
Coffin, V. et al, European Journal of Pharmacology, 256 (1994) R9-R10. "Selective antagonism of the anticonvulsant effects of felbamate by glycine".
Corbett, R. et al, Drug Development Research 24:201-205 (1991), "Effects of HA-966 on Conflict, Social Interaction, and Plus Maze Behaviors".
Cornford, E.M. et al, Epilepsia, 37(1):15-18, 1996, "Distribution of Felbamate in Brain".
Cotman, C.W. et al, Ann. Rev. Neurosci. 1988 11:61-80, "Excitatory Amino Acid Neurotransmission: NMDA Receptors and Hebb-Type Synaptic Plasticity".
Croucher, M.J. et al, Brain Research, 543 (1991) 91-96, "The influence of strychnine-insensitive glycine receptor agonists and antagonists on generalized seizure thresholds".
Croucher, M .J. et al, Neuroscience Letters, 118 (1990) 29-32, "7-Chlorokynurenic acid, a strychnine-insensitive glycine receptor antagonist, inhibits limbic seizure kindling".
During, M.J. et al, The Lancet, vol 341, Jun. 26, 1993, 1607-1610, "Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain".
De Sarro, Giovambattista et al, European Journal of Pharmacology 262 (1944) 11-19, "Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA2 mice".
Fink, K. et al, Naunyn-Schmiedeberg's Arch Pharmacol (1995) 352:394-401, "Stimulation of serotonin release in the rat brain cortex by activation of ionotropic glutamate receptors and its modulation via .alpha..sub.2 -heteroreceptors".
Finkelstein, J.E. et al, Pharmacoloqy Biochemistry and Behavior, vol. 49, No. 3, pp. 707-710, 1994, "Milacemide Treatment in Mice Enhances Acquisition of a Morris-Type Water Maze Task".
Fisher, M. et al, Stroke, vol. 25, No. 5, May 1994 "Prophylactic Neuroprotection for Cerebral Ischemia".
Fishkin, R.J. et al, Behavioral and Neural Biology, 59, 150-157 (1993), "D-Cycloserine Attenuates Scopolamine-lnduced Learning and Memory Deficits in Rats".
Heyes, M.P. et al, Journal of the Neurological Sciences 133 (1995) 112-118. "Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children".
Hill, R.R. et al, Psychosomatics, pp. 404-406, "Secondary Mania Associated With the Use of Felbamate".
Hutson, P.H, et al, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, pp. 2037-2044, "R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine".
Imamura, Y. et al, The Journal of Pharmacology and Experimental Therapeutics, vol. 275, No. 1, pp. 177-182, "Felbamate Relieves Several Abnormal Pain Sensations in Rats with an Experimental Peripheral Neuropathy".
Kemp, J .A. et al, 1993, Elsevier Science Publishers Ltd (UK), TIPS-Jan.
Kerrick, M. et al, Neurology 45, Jan. 1995, pp. 185-187, "Involuntary movement disorders associated with felbamate".
J. Clin Psychopharmacol, vol. 15/No. 4, Aug. 1995, pp. 292-293, "Psychosis Associates with Felbamate Treatment".
Harmsworth, W.L. et al, Epilepsia, vol. 34, Suppl. 2, 1993, pp. 92-93, "Felbamate Modulates Glycine Receptor Function".
Kretschmer, Beate D., Neuroscience Letters 179 (1994) 115-118, "Felbamate, an anti-convulsive drug, has anti-partinsonian potential in rats".
Leeson, P.D. et al, Journal of Medicinal Chemistry, vol. 37, No. 24,. Nov. 25, 1994, "The Glycine Site on the NMDA Recpetor:Structure-Activity Relationships and Therapeutic Potential".
Lipton, S.A. et al, Mechanisms of Disease-Lipton and Rosenberg, vol. 330, No. 9, pp. 613-622, "Excitatory Amino Acids As A Final Common Pathway For Neurologic Disorders".
McBain, C.J. et al, Physiological Reviews, vol. 74, No. 3, Jul. 1994, pp. 723-760, "N-Methyl-D-Aspartic Acid Receptor Structure and Function".
McCabe, R.T. et al, The Journal of Pharmacology and Experimental Therapeutics, vol. 264, No. 3, pp. 1248-1252, "Evidence for Anticonvulsant and Neuroprotectant Action of Felbamate Mediated by Strychnine-Insensitive Glycine Receptors".
Mellick, Gary A., DO, Journal of Pain and Symptom Management, vol. 10, No. 5, Jul. 1995, pp. 392-395, "Hemifacial Spasm: Successful Treatment with Felbamate".
Millian, M.J. et al, Neuroscience Letters 178 (1994) 139-143, "Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-0aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice".
Miyoshi, R. et al, Synapse 6:338-343 (1990), "Age-Related Changes of Strychnine-insensitive Glycine Receptors in Rat Brain" as Studies by In Vitro Autoradiography.
Monaghan, D.T. et al, Annu. Rev. Pharmacol. Toxicol, 1989, 29:365-402, "The Excitatory Amino Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the Function of the Central Nervous System".
Ney, G.C. et al, Neurology, May 1994, pp. 980-981, "Thrombocytopenia in association with adjunctive felbamate use".
Olney, J.W. et al, Arch Gen Psychiatry, vol. 52 Dec. 1995, pp.998-1007, "Glutamate Receptor Dysfunction and Schizophrenia".
O'Neil, M.G. et al, Letters, The Annals of Pharmacotherapy, 1995 Apr., vol. 29, p.430, "Felbamate-induced delayed anaphylaxis".
Pennell, P.B., et al, Neurology, Mar. 1995, 45:456-460, "Aplastic anemia in a patient receiving felbamate for complex partial seizures".
Priestley, T., et al, Brain Research, 531 (1990) 183-188, "The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures".
Reynolds, G.P., et al, Journal of the Neurological Sciences, 125 (1994) site of the glutamate/NMDA recept
Aulakh Charanjit S.
Ivy C Warren
LandOfFree
Methods of providing neuroprotection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of providing neuroprotection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of providing neuroprotection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-958079